Re: [Gnumed-devel] gmDrugs

[Ian Haywood]

On Fri, Oct 04, 2002 at 08:38:55PM +0200, Hilmar Berger wrote:
> 
> Second, it could be difficult to translate available drug databases to the
> hierarchic class design. The process of adaption would probably mean
> changes of the supplied information, which in turn means that you can't
> rely any more on the fact that the drug information is the one supplied by
> the manufacturer. That bears legal dangers, IMHO.
That is not any intention. Databases which already have done it 'the
hard way' by having, say, seperate entries for the interaction between
rifampicin and every oral contraceptive on the market, can import
that data as is, and not link to classes at all.

However, AMH and WHO/BNF use class-based monographs, their interaction
tables are also class-based. MIMS, remarkably, also has class-effects in
its database.

In any case, AMH and WHO/BNF are *not* manufacturer-based (which is why
we what to use them ;-)


Ian